Targeting Treatment-Resistant Colorectal Cancers
An investigational therapeutic targets egions of the epidermal growth factor receptor in patients whose colorectal cancers became resistant.
Progress Against Cancer
An investigational therapeutic targets egions of the epidermal growth factor receptor in patients whose colorectal cancers became resistant.
Study finds an association between the use of cholesterol-lowering statins and the risk of death lung cancer death among patients with the disease.
Men with metastatic, castrate-resistant prostate cancer with mutations in genes linked to DNA repair responded to an investigational targeted therapeutic.
A small, early-phase trial of an investigational cancer immunotherapy yielded "durable responses" for patients with advanced melanoma and ocular melanoma.
Trial data first presented at the AACR Annual Meeting 2014, showed drug doubled progression-free survival for a certain type of metastatic breast cancer.
Research is beginning to reveal that the metabolic health problems often associated with being or obese can themselves influence risk for certain cancers.
The FDA's approval of a targeted therapeutic called lenvatinib provides another option for patients certain forms of thyroid cancer.
The FDA has approved of a treatment for Waldenström's macroglobulinemia, a rare form of non-Hodgkin lymphoma. Learn more.
Drinking about four cups of coffee a day appears to reduce the risk of developing endometrial cancer, a British study reports. Women who drank about four cups of coffee per day appeared to have...
The FDA recently approved new therapeutics for acute lymphoblastic leukemia, metastatic melanoma, and advanced ovarian cancer. In December 2014, the U.S. Food and Drug Administration (FDA) issued three approvals for new medications to treat...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More